Page 18«..10..17181920..30..»

Archive for the ‘Regenerative Medicine’ Category

Regenerative Medicine Market in the US 2012 2016 – Video


Regenerative Medicine Market in the US 2012 2016

By: Anjali Kalan

Original post:
Regenerative Medicine Market in the US 2012 2016 - Video

Urine Stem Cells! Regenerative Medicine Breakthrough (Brainstorm Ep149) – Video


Urine Stem Cells! Regenerative Medicine Breakthrough (Brainstorm Ep149)
Annotations are not working so those will be added later. Shirts and Stuff http://www.zazzle.com/qdragon Follow us on Twitter https://twitter.com/BrainstormS...

By: qdragon1337

Go here to read the rest:
Urine Stem Cells! Regenerative Medicine Breakthrough (Brainstorm Ep149) - Video

Alliance for Regenerative Medicine – Part One – Video


Alliance for Regenerative Medicine - Part One
John Lewis of ACRO sits down to talk with Michael Werner, Executive Director of the Alliance for Regenerative Medicine (ARM), about who they are, clinical tr...

By: ACROHealthChannel

Visit link:
Alliance for Regenerative Medicine - Part One - Video

Alliance for Regenerative Medicine – Part Three – Video


Alliance for Regenerative Medicine - Part Three
John Lewis of ACRO sits down to talk with Michael Werner, Executive Director of the Alliance for Regenerative Medicine (ARM) about who they are, their policy...

By: ACROHealthChannel

Read this article:
Alliance for Regenerative Medicine - Part Three - Video

Alliance for Regenerative Medicine – Part Two – Video


Alliance for Regenerative Medicine - Part Two
John Lewis of ACRO sits down to talk with Michael Werner, Executive Director of the Alliance for Regenerative Medicine (ARM), about who they are, experimenta...

By: ACROHealthChannel

Read this article:
Alliance for Regenerative Medicine - Part Two - Video

Alliance for Regenerative Medicine – Part Four – Video


Alliance for Regenerative Medicine - Part Four
John Lewis of ACRO sits down to talk with Michael Werner, Executive Director of the Alliance for Regenerative Medicine (ARM) about who they are, their regula...

By: ACROHealthChannel

Read this article:
Alliance for Regenerative Medicine - Part Four - Video

John Barker – Regenerative medicine and body cures – Video


John Barker - Regenerative medicine and body cures
Regeneration to most of us conjures up a scene from a long forgotten science fiction movie, but John Barker, Director, Frankfurt Initiative for Regenerative ...

By: IFTV

View original post here:
John Barker - Regenerative medicine and body cures - Video

What is Regenerative Medicine? – Video


What is Regenerative Medicine?
Learn about regenerative medicine related research being conducted at Johns Hopkins University via the Institute for NanoBioTechnology (INBT). This video was...

By: INBT Johns Hopkins

Read the rest here:
What is Regenerative Medicine? - Video

Now, MSc in Regenerative Medicine – The New Indian Express – Video


Now, MSc in Regenerative Medicine - The New Indian Express
I created this video with the YouTube Slideshow Creator (http://www.youtube.com/upload)

By: Hiren Shukla

View original post here:
Now, MSc in Regenerative Medicine - The New Indian Express - Video

Streamlined regulation would be welcome but Government clearly supports regenerative medicines research, say experts

Earlier this week the House of Lords' ScienceandTechnologyCommitteepublished a report in which it said that the UK is "currently underprepared to realise the full potential of regenerative medicine".

Among the criticisms the Committee raised was with the regulatory regime that applies in the UK to regenerative medicines and with the level of Government funding to help the industry grow.

Life sciences transactions lawyer Allistair Booth of Pinsent Masons, the law firm behind Out-Law.com, said that the Government had demonstrated its commitment to the growth of regenerative medicines research in the UK.

"Regenerative medicines is one of the next big areas for medical research," Booth said. "The Government has put together centres of excellence around cutting edge technology with the idea of combining research and catapulting it forward. The Cell Therapy Catapult is one of the centres set to benefit from the Chancellor's decision to ring fence 185 million for scientific research in his recent Spending Review."

"Through, for example, the Cell Therapy Catapult and the government funding of that Catapult, small regenerative medicine research companies can get access to equipment, expertise and the other resources that would most likely otherwise be beyond their reach," he said. "The reality is that, while a number of early stage venture funds have been created in the last few years and that is a very welcome development there is still a shortage of early stage investment capital to assist these companies to take forward such cutting edge innovation."

"Through its investment in the various Catapults and the BioMedical Catalyst fund the UK Government is providing vital, meaningful and very welcome support to innovative life sciences companies to move forward their research to the point where it can attract further investment or partnering opportunities," said Booth.

In its report, the ScienceandTechnologyCommitteesaid it was concerned that the Cell Therapy Catapult was "seeking to achieve too much, too quickly, given the level of funding" available to it. The Cell Therapy Catapult, set up in 2012, had an initial budget of approximately 70m to be spread over five years, but the Committee said that it should prioritise "developing investable propositions and building connections" before sharing its expertise.

The Committee also said that "innovative funding models" should be explored to help support the development of regenerative medicines research. It said the models would likely rely on the Government matching funds pledged or providing a form of guarantee to investments and that the Government should "put their money where their mouth is".

The Committee also called for action to help reduce regulatory barriers to the development of the regenerative medicines research in the UK. It said that the Health Research Authority (HRA) must "simplify the regulatory route so that the development of regenerative medicine, and other innovative therapies, is not hindered". A new independent advisory group should be set up to assist the HRA in helping "focus and clarify the functions of regulators".

Life sciences expert Louise Fullwood of Pinsent Masons said she agreed with the Committee's view that the existing regulatory framework was 'labyrinthine'.

Follow this link:
Streamlined regulation would be welcome but Government clearly supports regenerative medicines research, say experts

Regenerative Medicines: Bone and Joint Applications

NEW YORK, July 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Regenerative Medicines: Bone and Joint Applications http://www.reportlinker.com/p0157460/Regenerative-Medicines-Bone-and-Joint-Applications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

INTRODUCTION

Regenerative medicine in orthopedic applications is a $2.7 billion per year niche sector in America's $2.6 trillion per year healthcare system. However, it is a sector of immense interest in terms of technical and medical possibilities. The best analogy to the current state of regenerative therapies in the bone and joint healing sector is the nascency of the microprocessors business back in 1971. At that time, microprocessors (namely Intel's 4004), and related innovations, were just an infinitesimal segment of electronic component sales, but this innovation came to dominate the economy. The regenerative therapies sector, particularly areas such as cell therapy and stem cell derived products is in a comparable position today.

The regenerative medicine industry has been in existence for nearly 25 years. Actual product sales, along with research and development (R&D) expenditures, are projected to amount to approximately $2.7 billion in economic activity in 2013, of which venture capital and R&D funding accounts for about $145 million. The rapid evolution of this business is evidenced by the industry consolidation that has occurred since the first edition of this BCC Research report was published in 2003 and even since the most recent edition in 2009. Innumerable buyouts, consolidations, product abandonments, new firms and a few bankruptcies, too, have occurred in just the last several years. These changes are reflected in the Company Profiles section of this report. In addition, intensive R&D efforts at universities, the National Institutes of Health, the National Science Foundation and at FDA centers that focus on cuttingedge technology underscore the importance of this industry.

Regenerative therapies have the potential to improve medical outcomes, enhance quality of life, and reduce overall healthcare costs. A key objective is the utilization of living cells to repair or replace body tissue damaged by injury, disease, or the aging process. The most successful products have drawn upon multidisciplinary fields such as biology, medicine, engineering, and, particularly, biomedical engineering.

The principal focus in this report is on bone and joint applications; however, other regenerative applications such as dental, neurologic, organ regeneration, cardiovascular, urologic, diabetes, and wound care are important and are briefly covered to underscore the larger importance of regenerative therapies. Stemcell research is an important component of the sector as well. For example, the successful differentiation of embryonic stem cells into specific cell types is widely sought as a means to treat traumatic spinalcord injury, as well as diseases such as diabetes, Duchenne muscular dystrophy, heart disease, and vision and hearing loss.

OBJECTIVES AND GOALS OF STUDY

This report focuses on the bone and jointrelated applications of and markets for the various categories of regenerative medicine products currently available and projected to be introduced during the fiveyear forecast period from 2013 through 2018. Market drivers discussed include the status of R&D and what is likely to issue from R&D in the way of actual products and therapies. Other market drivers include the incidence, and rate of growth, of diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (e.g., hip fractures, knee injuries); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone and cartilagegrowthstimulating agents in a regenerative appliance. Products discussed include bone and cartilage grafting and regenerative products derived from autologous, allogeneic, and synthetic sources, as well as electrical stimulators for bone growth and regenerative cartilage products.

Profiles are provided of leading and emerging companies in the bone and joint regenerative medicine markets, along with analyses of the current and future positioning of their products and businesses in this active and rapidly changing market. Developmental and clinical stage companies are well covered.

Read more:
Regenerative Medicines: Bone and Joint Applications

Research and Markets: Regenerative Medicine Markets – 2013 Report

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/23dgtg/regenerative) has announced the addition of the "Regenerative Medicine Markets" report to their offering.

Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement.

This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures.

The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.

Key Topics Covered

1. Overview

2. Regenerative Medicines: An Overview of Segments

3. Regenerative Medicine: The Next Evolution of Medical Treatment

4. Recent Advances in Regenerative Medicine and Stem Cell Research

Read the original:
Research and Markets: Regenerative Medicine Markets - 2013 Report

MaSTherCell – World Stem Cells Regenerative Medicine Congress 2013 – Video


MaSTherCell - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Original post:
MaSTherCell - World Stem Cells Regenerative Medicine Congress 2013 - Video

Merck Millipore – World Stem Cells Regenerative Medicine Congress 2013 – Video


Merck Millipore - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Follow this link:
Merck Millipore - World Stem Cells Regenerative Medicine Congress 2013 - Video

Terumo BCT – World Stem Cells Regenerative Medicine Congress 2013 – Video


Terumo BCT - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Visit link:
Terumo BCT - World Stem Cells Regenerative Medicine Congress 2013 - Video

Quality Assistance S.A. – World Stem Cells Regenerative Medicine Congress – Video


Quality Assistance S.A. - World Stem Cells Regenerative Medicine Congress
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Go here to see the original:
Quality Assistance S.A. - World Stem Cells Regenerative Medicine Congress - Video

Savsu Technologies – World Stem Cells Regenerative Medicine Congress 2013 – Video


Savsu Technologies - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

See the article here:
Savsu Technologies - World Stem Cells Regenerative Medicine Congress 2013 - Video

Cell Therapy Catapult – World Stem Cells Regenerative Medicine Congress 2013 – Video


Cell Therapy Catapult - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

See the original post here:
Cell Therapy Catapult - World Stem Cells Regenerative Medicine Congress 2013 - Video

The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (Part 7 of 7) – Video


The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 7 of 7)
In this final segment, Prof. Caplan discusses: Mesenchymal stem cells make anti-bacterial molecules, How retro-orbital injections of human MSCs cure mice wit...

By: http://www.cellmedicine.com

View post:
The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 7 of 7) - Video

The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (Part 6) – Video


The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 6)
In part 6, Prof. Caplan discusses Trophic properties of mesenchymal stem cells; MSCs for heart disease; MSCs homing to heart injury site and also to skin inc...

By: http://www.cellmedicine.com

View original post here:
The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 6) - Video

Keynote address – Lord John Krebs – World Stem Cells Regenerative Medicine Congress – Video


Keynote address - Lord John Krebs - World Stem Cells Regenerative Medicine Congress
Lord John Krebs, chairman of the House of Lords Science and Technology Committee gives his presentation on #39;Mapping a route for the commercialisation of cell...

By: biopharmachannel

Continue reading here:
Keynote address - Lord John Krebs - World Stem Cells Regenerative Medicine Congress - Video

Health economics – Prof. Richard Lilford – World Stem Cells Regenerative Medicine Congress 2013 – Video


Health economics - Prof. Richard Lilford - World Stem Cells Regenerative Medicine Congress 2013
Prof. Richard Lilford, Clinical Epidemiology, Public Health Biostatistics at the University of Birmingham gives his presentation on #39;Health economics: how ...

By: biopharmachannel

Read more:
Health economics - Prof. Richard Lilford - World Stem Cells Regenerative Medicine Congress 2013 - Video

Commercialisation through collaboration – Ed Field – World Stem Cells Regenerative Medicine – Video


Commercialisation through collaboration - Ed Field - World Stem Cells Regenerative Medicine
Ed Field, Chief Operating Officer at Cytomedix gives his presentation on #39;Commercialisation through collaboration: what does partnering in this industry actu...

By: biopharmachannel

Original post:
Commercialisation through collaboration - Ed Field - World Stem Cells Regenerative Medicine - Video

World Courier Logistics Ltd. – World Stem Cells Regenerative Medicine Congress 2013 – Video


World Courier Logistics Ltd. - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Continue reading here:
World Courier Logistics Ltd. - World Stem Cells Regenerative Medicine Congress 2013 - Video

Alternative financing models – Navid Malik – World Stem Cells Regenerative Medicine Congress – Video


Alternative financing models - Navid Malik - World Stem Cells Regenerative Medicine Congress
Navid Malik, Head of Life Science Research at Cenkos Securities gives his presentation on #39;Alternative financing models: floating on the stock markets to gai...

By: biopharmachannel

Go here to read the rest:
Alternative financing models - Navid Malik - World Stem Cells Regenerative Medicine Congress - Video

Archives